Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein (Monomer, MALS verified)

Wilms tumor gene 1 (WT1), is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The human HLA-A*2402 WT-1 (CYTWNQMNL) complex protein is a complex of HLA-A*2402 of the MHC Class I, B2M and CYTWNQMNL peptide of the WT-1.

Product Specifications

Background

Specifications

Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 35.8 kDa and 11.7 kDa. The protein migrates as 39-41 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

AAA59600.1 (HLA-A*24:02) & P61769 (B2M) & CYTWNQMNL

Expression Region

Gly 25 - Thr 305 (HLA-A*24:02) & Ile 21 - Met 119 (B2M) & CYTWNQMNL peptide

Host

HEK293

Target

HLA-A*2402 & B2M & WT-1 (CYTWNQMNL)

Conjugation

Biotin-labeled

Tag

C-10xHis & C-Avi

Source

Human

Stability

The product MUST be stored at -70°C or lower upon receipt; -70°C for 3 months under sterile conditions.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein (Cat. No. HLW-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (QC tested).